Receiving a diagnosis of prostate cancer can be frightening and confusing. Understanding the details of your specific cancer and how they relate to your prognosis and treatment planning is an important first step toward shared decision-making between you and your physicians. In these CURE Connections programs you will learn the meaning of the PSA test, prostate cancer staging and grading, and how these factors are used to determine which treatment approach is right for you. Management of prostate cancer related symptoms, available treatments, and how to deal with side effects are also discussed. In addition, you will hear from patients and caregivers about their personal experiences with prostate cancer.
What do Bill Nye the Science Guy, fashion designer Michael Kors and one very special prostate cancer advocate all have in common? Blue jackets, a runway and the ultimate goal of raising awareness for prostate cancer.
The Food and Drug Administration granted Xtandi (enzalutamide) a priority review to a supplemental new drug application for the treatment of patients with nonmetastatic castration-resistant prostate cancer, according to the companies developing the drug, Pfizer and Astellas.
The Food and Drug Administration (FDA) approved Erleada (apalutamide) for the treatment of patients who have nonmetastatic castration-resistant prostate cancer (CRPC). The drug is now the first FDA-approved treatment in this setting.
The Virtual Environment Radiotherapy Training (VERT™) system, originally designed to teach medical students and physicians about administering radiation therapy, is being used to explain to people who have prostate cancer what their treatment will look like.
The FDA has granted a priority review to a new drug application (NDA) for apalutamide (ARN-509) for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC), according to Janssen Biotech, the manufacturer of the next-generation oral androgen receptor inhibitor.
Data from a pilot study showed an added benefit from the incorporation of extra virgin olive oil into the diets of men with low-risk prostate cancer. As a result, this dietary modification could lead to weight loss, while also helping the body to absorb compounds with anticancer properties.